Unicycive Therapeutics (UNCY) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.
The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.
Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.
Unicycive shares were nearly 3% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments